BioCentury
ARTICLE | Financial News

Cancer play FLX raises $50M in series B

April 27, 2016 1:14 AM UTC

FLX Bio Inc. (South San Francisco, Calif.) raised $50 million in a series B round with The Column Group, Topspin Partners, Kleiner Perkins Caufield & Byers and Celgene Corp. (NASDAQ:CELG). FLX's lead product, FLX925, is a small molecule inhibitor of FMS-like tyrosine kinase 3 ( FLT3; CD135), cyclin dependent kinase 4 ( CDK4) and CDK6 that is in Phase I testing to treat relapsed or refractory acute myelogenous leukemia (AML). ...